Skip to main content
SpringerLink
Log in

Medical Management of Children with Juvenile Rheumatoid Arthritis

  • Disease Management
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

One of the most important and changing areas of research in paediatric rheumatology is the optimum approach to the treatment of children with chronic arthritis. Until recently all medications for children with arthritis were nonspecific in terms of our understanding, albeit poor, of the pathogenesis of these diseases. Of current therapies, low dose, once-a-week methotrexate has emerged as the therapeutic agent of choice for children who fail to respond adequately to administration of a nonsteroidal anti-inflammatory drug. Thereby, it has displaced the more traditional slower acting anti-rheumatic drugs, although one or more of them are often combined with methotrexate in the polypharmaceutical approach to childhood arthritis.

Better and more specific agents are needed, especially for systemic onset disease, unremitting polyarticular involvement, and certain complications such as resistant chronic uveitis. At this time the introduction of the cyclo-oxygenase 2 inhibitors and etanercept (soluble tumour necrosis factorα.p75 fusion protein) may herald an era of more specific and effective therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cassidy JT, Petty RE. Textbook of pediatric rheumatology. 3rd ed. Philadelphia: WB Saunders, 1995

    Google Scholar 

  2. Cron RQ, Sharma S, Sherry DD. Current treatment by United States and Canadian pediatric rheumatologists. J Rheumatol 1999; 26: 2036–8

    PubMed  CAS  Google Scholar 

  3. Lindsley CB. Uses of nonsteroidal anti-inflammatory drugs in pediatrics. Am J Dis Child 1993; 147: 229–36

    PubMed  CAS  Google Scholar 

  4. Keenan GF, Giannini EH, Athreya BH. Clinically significant gastropathy associated with nonsteroidal antiinflammatory drug use in children with juvenile rheumatoid arthritis. J Rheumatol 1995; 22: 1149–51

    PubMed  CAS  Google Scholar 

  5. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 413–21

    Article  PubMed  CAS  Google Scholar 

  6. Golden BD, Abramson SB. Selective cyclooxygenase-2 inhibitors. Rheum Dis Clin North Am 1999; 25: 359–78

    Article  PubMed  CAS  Google Scholar 

  7. Rumack, B. Asprin and acetaminophen. Pediatrics 1978; (Suppl.) 62: 86S-94S

  8. Pachman LM, Olufs R, Procknal JA, et al. Pharmacokinetic monitoring of salicylate therapy in children with juvenile rheumatoid arthritis. Arthritis Rheum 1979; 22: 826–31

    Article  PubMed  CAS  Google Scholar 

  9. Poe TE, Mutchie KD, Saunders GH, et al. Total and free salicylate concentrations in juvenile rheumatoid arthritis. J Rheumatol 1980; 7: 717–23

    PubMed  CAS  Google Scholar 

  10. Kvien TK, Olsson B, Hoyeraal HM. Acetylsalicylic acid and juvenile rheumatoid arthritis: effect of dosage interval on the serum salicylic acid level. Acta Paediatr Scand 1985; 74: 755–9

    Article  PubMed  CAS  Google Scholar 

  11. Weaver AL, Sullivan RE, Kramer WS. Iatrogenic tooth erosions in juvenile rheumatoid arthritis patients [abstract]. Clin Res 1982; 30: 810A

    Google Scholar 

  12. Tanchyk AR Prevention of tooth erosion from salicylate therapy in juvenile rheumatoid arthritis. Gen Dent 1986; 34: 479–80

    PubMed  CAS  Google Scholar 

  13. Hurwitz ES, Barrett MJ, Bregman D, et al. Public Health Service study of Reye’s syndrome and medications. Report of the main study [published erratum appears in JAMA 1987 Jun 26; 257 (24): 3366]. JAMA 1987; 257: 1905–11

    Article  PubMed  CAS  Google Scholar 

  14. Ulshen MH, Grand RJ, Crain JD, et al. Hepatoxicity with encephalopathy associated with aspirin therapy in rheumatoid arthritis. J Pediatr 1978; 93: 1034–7

    Article  PubMed  CAS  Google Scholar 

  15. Rennebohm RM, Heubi JE, Daugherty CC, et al. Reye syndrome in children receiving salicylate therapy for connective tissue disease. J Pediatr 1985; 107: 877–80

    Article  PubMed  CAS  Google Scholar 

  16. Remington PL, Shabino CL, McGee H, et al. Reye syndrome and juvenile rheumatoid arthritis in Michigan. Am J Dis Child 1985; 139: 870–2

    PubMed  CAS  Google Scholar 

  17. Kauffman RE, Roberts RJ. Aspirin use and Reye syndrome. Pediatrics 1987; 79: 1049–50

    PubMed  CAS  Google Scholar 

  18. Arrowsmith JB, Kennedy DL, Kuritsky JN, et al. National patterns of aspirin use and Reye syndrome reporting, United States, 1980 to 1985. Pediatrics 1987; 79: 858–63

    PubMed  CAS  Google Scholar 

  19. Steans A, Manners PJ, Robinson IG. A multicentre, long-term evaluation of the safety and efficacy of ibuprofen syrup in children with juvenile chronic arthritis. Br J Clin Pract 1990; 44: 172–175

    PubMed  CAS  Google Scholar 

  20. Giannini EH, Brewer EJ, Miller ML, et al. Ibuprofen suspension in the treatment of juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. J Pediatr 1990; 117: 645–52

    CAS  Google Scholar 

  21. Makela AL. Naproxen in the treatment of juvenile rheumatoid arthritis: metabolism, safety and efficacy. Scand J Rheumatol 1977; 6: 193–205

    Article  PubMed  CAS  Google Scholar 

  22. Moran H, Hanna DB, Ansell BM, et al. Naproxen in juvenile chronic polyarthritis. Ann Rheum Dis 1979; 38: 152–4

    Article  PubMed  CAS  Google Scholar 

  23. Nicholls A, Hazleman B, Todd RM, et al. Long-term evaluation of naproxen suspension in juvenile chronic arthritis. CurrMed Res Opin 1982; 8: 204–7

    Article  CAS  Google Scholar 

  24. Laxer RM, Silverman ED, St-Cyr C, et al. A six-month open safety assessment of a naproxen suspension formulation in the therapy of juvenile rheumatoid arthritis. Clin Ther 1988; 10: 381–7

    PubMed  CAS  Google Scholar 

  25. Leak AM, Richter MR, Clemens LE, et al. A crossover study of naproxen, diclofenac and tolmetin in seronegative juvenile chronic arthritis. Clin Exp Rheumatol 1988; 6: 157–60

    PubMed  CAS  Google Scholar 

  26. Levinson JE, Baum J, Brewer EJ, et al. Comparison of tolmetin sodium and aspirin in the treatment of juvenile rheumatoid arthritis. J Pediatr 1977; 91: 799–804

    Article  PubMed  CAS  Google Scholar 

  27. Gewanter HL, Baum J. The use of tolmetin sodium in systemic onset juvenile rheumatoid arthritis. Arthritis Rheum 1981; 24: 1316–9

    Article  PubMed  CAS  Google Scholar 

  28. Todd PA, Sorkin EM. Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy [published erratum appears in Drugs 1988 Jul; 36 (1): preceding 1]. Drugs 1988; 35: 244–85

    Article  PubMed  CAS  Google Scholar 

  29. Minisola G, Dardano B, Calderazzo L, et al. Clinical efficacy of sodium diclofenac in chronic juvenile polyarthritis. Pediatr Med Chir 1990; 12: 169–73

    PubMed  CAS  Google Scholar 

  30. Makela AL, Lempiainen M, Ylijoki H. Ibuprofen levels in serum and synovial fluid. Scand J Rheumatol Suppl 1981; 39: 15–7

    Article  PubMed  CAS  Google Scholar 

  31. Brewer EJJ. A comparative evaluation of indomethacin, acetaminophen and placebo as antipyretic agents in children. Arthritis Rheum 1968; 11: 645–51

    Article  PubMed  Google Scholar 

  32. Sherry DD, Patterson MW, Petty RE. The use of indomethacin in the treatment of pericarditis in childhood. J Pediatr 1982; 100: 995–8

    Article  PubMed  CAS  Google Scholar 

  33. Jacobs JS. Sudden death in arthritic children receiving large doses of indomethacin. JAMA 1967; 199: 932–4

    Article  PubMed  CAS  Google Scholar 

  34. Lovell DJ, Giannini EH, Brewer EJJ. Time course of response to nonsteroidal antiinflammatory drugs in juvenile rheumatoid arthritis. Arthritis Rheum 1984; 27: 1433–7

    Article  PubMed  CAS  Google Scholar 

  35. Athreya BH, Moser G, Cecil HS, et al. Aspirin-induced hepatotoxicity in juvenile rheumatoid arthritis: a prospective study. Arthritis Rheum 1975; 18: 347–52

    Article  PubMed  CAS  Google Scholar 

  36. Wortmann DW, Kelsch RC, Kuhns L, et al. Renal papillary necrosis in juvenile rheumatoid arthritis. J Pediatr 1980; 97: 37–40

    Article  PubMed  CAS  Google Scholar 

  37. Allen RC, Petty RE, Lirenman DS, et al. Renal papillary necrosis in children with chronic arthritis. Am J Dis Child 1986; 140: 20–2

    PubMed  CAS  Google Scholar 

  38. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991; 31: 588–98

    PubMed  CAS  Google Scholar 

  39. Allen R, Rogers M, Humphrey I. Naproxen induced pseudoporphyria in juvenile chronic arthritis. J Rheumatol 1991; 18: 893–6

    PubMed  CAS  Google Scholar 

  40. Wallace CA, Farrow D, Sherry DD. Increased risk of facial scars in children taking nonsteroidal antiinflammatory drugs. J Pediatr 1994; 125: 819–22

    Article  PubMed  CAS  Google Scholar 

  41. Levy ML, Barron KS, Eichenfield A, et al. Naproxen-induced pseudoporphyria: a distinctive photodermatitis. J Pediatr 1990; 117: 660–4

    Article  PubMed  CAS  Google Scholar 

  42. Lang BA, Finlayson LA. Naproxen-induced pseudoporphyria in patients with juvenile rheumatoid arthritis. J Pediatr 1994; 124: 639–42

    Article  PubMed  CAS  Google Scholar 

  43. Girschick HJ, Hamm H, Ganser G, et al. Naproxen-induced pseudoporphyria: appearance of new skin lesions after discontinuation of treatment. Scand J Rheumatol 1995; 24: 108–11

    Article  PubMed  CAS  Google Scholar 

  44. Truckenbrodt H, Hafner R. Methotrexate therapy in juvenile rheumatoid arthritis: a retrospective study. Arthritis Rheum 1986; 29: 801–745.

    Article  PubMed  CAS  Google Scholar 

  45. Speckmaier M, Findeisen J, Woo P, et al. Low-dose methotrexate in systemic onset juvenile chronic arthritis. Clin Exp Rheumatol 1989; 7: 647–50

    PubMed  CAS  Google Scholar 

  46. Halle F, Prieur AM. Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype. Clin Exp Rheumatol 1991; 9: 297–302

    PubMed  CAS  Google Scholar 

  47. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med 1992; 326: 1043–9

    CAS  Google Scholar 

  48. Lovell DJ. Ten years of experience with methotrexate: past, present and future. Rev Rhum Engl Ed 1997; 64: 186S–8S

    PubMed  CAS  Google Scholar 

  49. Singsen BH, Goldbach-Mansky R. Methotrexate in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and nonrheumatic disorders. Rheum Dis Clin North Am 1997; 23: 811–40

    Article  PubMed  CAS  Google Scholar 

  50. Wallace CA. The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum 1998; 41: 381–91

    Article  PubMed  CAS  Google Scholar 

  51. Cassidy JT. Outcomes research in the therapeutic use of methotrexate in children with chronic peripheral arthritis [editorial]. J Pediatr 1998; 133: 179–80

    Article  PubMed  CAS  Google Scholar 

  52. Wallace CA, Levinson JE. Juvenile rheumatoid arthritis: outcome and treatment for the 1990s. Rheum Dis Clin North Am 1991; 17: 891–905

    PubMed  CAS  Google Scholar 

  53. Giannini EH, Cassidy JT, Brewer EJ, et al. Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. Semin Arthritis Rheum 1993; 23: 34–46

    Article  PubMed  CAS  Google Scholar 

  54. Dupuis LL, Koren G, Silverman ED, et al. Influence of food on the bioavailability of oral methotrexate in children. J Rheumatol 1995; 22: 1570–3

    PubMed  CAS  Google Scholar 

  55. Wallace CA, Sherry DD, Mellins ED, et al. Predicting remission in juvenile rheumatoid arthritis with methotrexate treatment. J Rheumatol 1993; 20: 118–22

    PubMed  CAS  Google Scholar 

  56. Giannini EH, Cassidy JT. Methotrexate in juvenile rheumatoid arthritis: do the benefits outweigh the risks? Drug Saf 1993; 9: 325–39

    Article  PubMed  CAS  Google Scholar 

  57. Wallace CA, Sherry DD. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J Rheumatol 1992; 19: 1604–7

    PubMed  CAS  Google Scholar 

  58. Reiff A, Shaham B, Wood BP, et al. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 113–8

    PubMed  CAS  Google Scholar 

  59. Ravelli A, Gerloni V, Corona F, et al. Oral versus intramuscular methotrexate in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group. Clin Exp Rheumatol 1998; 16: 181–3

    CAS  Google Scholar 

  60. Wallace CA, Bleyer WA, Sherry DD, et al. Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. Arthritis Rheum 1989; 32: 677–81

    Article  PubMed  CAS  Google Scholar 

  61. Wallace CA, Sherry DD. A practical approach to avoidance of methotrexate toxicity [editorial]. J Rheumatol 1995; 22: 1009–12

    PubMed  CAS  Google Scholar 

  62. Albertioni F, Flato B, Seideman P, et al. Methotrexate in juvenile rheumatoid arthritis: evidence of age-dependent pharmacokinetics. Eur J Clin Pharmacol 1995; 47: 507–11

    Article  PubMed  CAS  Google Scholar 

  63. Hunt PG, Rose CD, McIlvain-Simpson G, et al. The effects of daily intake of folic acid on the efficacy of methotrexate therapy in children with juvenile rheumatoid arthritis: a controlled study. J Rheumatol 1997; 24: 2230–2

    PubMed  CAS  Google Scholar 

  64. Martini A, Ravelli A, Viola S, et al. Methotrexate hepatotoxic effects in children with juvenile rheumatoid arthritis [letter]. J Pediatr 1991; 119: 333–4

    PubMed  CAS  Google Scholar 

  65. Hashkes PJ, Balistreri WF, Bove KE, et al. The long-term effect of methotrexate therapy on the liver in patients with juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40: 2226–34

    Article  PubMed  CAS  Google Scholar 

  66. Hashkes PJ, Balistreri WF, Bove KE, et al. The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1999; 134: 47–52

    Article  PubMed  CAS  Google Scholar 

  67. Kremer JM, Alarcon GS, Lightfoot RWJ, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994; 37: 316–28

    CAS  Google Scholar 

  68. Wallace CA, Smith AL, Sherry DD. Pilot investigation of naproxen/methotrexate interaction in patients with juvenile rheumatoid arthritis. J Rheumatol 1993; 20: 1764–8

    PubMed  CAS  Google Scholar 

  69. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202–9

    PubMed  CAS  Google Scholar 

  70. Ruperto N, Ravelli A, Falcini F, et al. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Italian Pediatric Rheumatology Study Group. Ann Rheum Dis 1998; 57: 38–41

    CAS  Google Scholar 

  71. Ruperto N, Ravelli A, Falcini F, et al. Responsiveness of outcome measures in juvenile chronic arthritis. Italian Pediatric Rheumatology Study Group. Rheumatology (Oxford) 1999; 38: 176–80

    CAS  Google Scholar 

  72. Moroldo MB, Giannini EH. Estimates of the discriminant ability of definitions of improvement for juvenile rheumatoid arthritis. J Rheumatol 1998; 25: 986–9

    PubMed  CAS  Google Scholar 

  73. Rose CD, Singsen BH, Eichenfield AH, et al. Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr 1990; 117: 653–9

    Article  PubMed  CAS  Google Scholar 

  74. Giannini EH, Cawkwell GD. Drug treatment in children with juvenile rheumatoid arthritis: past, present, and future. Pediatr Clin North Am 1995; 42: 1099–1125

    PubMed  CAS  Google Scholar 

  75. Ravelli A, Viola S, Ramenghi B, et al. Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. J Pediatr 1998; 133: 262–5

    Article  PubMed  CAS  Google Scholar 

  76. Harel L, Wagner-Weiner L, Poznanski AK, et al. Effects of methotrexate on radiologic progression in juvenile rheumatoid arthritis. Arthritis Rheum 1993; 36: 1370–4

    Article  PubMed  CAS  Google Scholar 

  77. Gottlieb BS, Keenan GF, Lu T, et al. Discontinuation of methotrexate treatment in juvenile rheumatoid arthritis. Pediatrics 1997; 100: 994–7

    Article  PubMed  CAS  Google Scholar 

  78. Weiss AH, Wallace CA, Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. J Pediatr 1998; 133: 266–8

    Article  PubMed  CAS  Google Scholar 

  79. Wallace CA. On beyond methotrexate treatment of severe juvenile rheumatoid arthritis. Clin Exp Rheumatol 1999; 17: 499–504

    PubMed  CAS  Google Scholar 

  80. Grondin C, Malleson P, Petty RE. Slow-acting antirheumatic drugs in chronic arthritis of childhood. Semin Arthritis Rheum 1988; 18: 38–47

    Article  PubMed  CAS  Google Scholar 

  81. Rosenberg AM. Treatment of juvenile rheumatoid arthritis: approach to patients who fail standard therapy. J Rheumatol 1996; 23: 1652–6

    PubMed  CAS  Google Scholar 

  82. Silverman ED, Miller JJ, Bernstein B, et al. Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. J Pediatr 1983; 103: 872–6

    Article  PubMed  CAS  Google Scholar 

  83. Jacobs JC, Gorin LJ, Hanissian AS, et al. Consumption coagulopathy after gold therapy for JRA [letter]. J Pediatr 1984; 105: 674–5

    Article  PubMed  CAS  Google Scholar 

  84. Manners PJ, Ansell BM. Slow-acting antirheumatic drug use in systemic onset juvenile chronic arthritis. Pediatrics 1986; 77: 99–103

    PubMed  CAS  Google Scholar 

  85. Barash J, Cooper M, Tauber Z. Hepatic, cutaneous and hematologic manifestations in juvenile chronic arthritis. Clin Exp Rheumatol 1991; 9: 541–3

    PubMed  CAS  Google Scholar 

  86. Prieur AM, Stephan JL. Macrophage activation syndrome in rheumatic diseases in children [in French]. Rev Rhum Ed Fr 1994; 61: 447–51

    PubMed  CAS  Google Scholar 

  87. Grom AA, Passo M. Macrophage activation syndrome in systemic juvenile rheumatoid arthritis [editorial]. J Pediatr 1996; 129: 630–2

    Article  PubMed  CAS  Google Scholar 

  88. Houpt JB. A rheumatologist’s verdict on the safety of chloroquine versus hydroxychloroquine: liability in Off-label prescribing. J Rheumatol 1999; 26: 1864–6

    PubMed  CAS  Google Scholar 

  89. Easterbrook M. An opthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine. J Rheumatol 1999; 26: 1866–7

    PubMed  CAS  Google Scholar 

  90. Esdaile JM. More thoughts about antimalarials: should one prescribe chloroquine? J Rheumatol 1999; 26: 1868

    PubMed  CAS  Google Scholar 

  91. Laaksonen AL, Koskiahde V, Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus: a clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine. Scand J Rheumatol 1974; 3: 103–8

    Article  PubMed  CAS  Google Scholar 

  92. Brewer EJ, Giannini EH, Kuzmina N, et al. Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis: results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial. N Engl J Med 1986; 314: 1269–76

    Article  PubMed  CAS  Google Scholar 

  93. Hamilton EBD, Scott JT. Hydroxychloroquine sulfate (‘Plaquenil’) in treatment of rheumatoid arthritis. Arthritis Rheum 1962; 5: 502–12

    Article  PubMed  CAS  Google Scholar 

  94. Markowitz HA, McGinley JM. Chloroquine poisoning in a child. JAMA 1964; 189: 950–1

    Article  PubMed  CAS  Google Scholar 

  95. Sassaman FW, Cassidy JT, Alpern M, et al. Electroretinography in patients with connective tissue diseases treated with hydroxychloroquine. Am J Ophthalmol 1970; 70: 515–23

    PubMed  CAS  Google Scholar 

  96. Maksymowych W, Russell AS. Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 1987; 16: 206–21

    Article  PubMed  CAS  Google Scholar 

  97. Rynes RI. Ophthalmologic considerations in using antimalarials in the United States. Lupus 1996; 5 Suppl. 1: S73–4

    Article  PubMed  CAS  Google Scholar 

  98. Rynes RI. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol 1997; 36: 799–805

    Article  PubMed  CAS  Google Scholar 

  99. Stillman JS. Antimalarials in the treatment of juvenile rheumatoid arthritis. In: Moore TD, editor. Arthritis in childhood: report of the Eightieth Ross Conference in Pediatric Research. Columbus, Ohio: Ross Laboratories, 1981: 125

    Google Scholar 

  100. Van Kerckhove C, Giannini EH, Lovell DJ. Temporal patterns of response to D-penicillamine, hydroxychloroquine, and placebo in juvenile rheumatoid arthritis patients. Arthritis Rheum 1988; 31: 1252–8

    Article  PubMed  Google Scholar 

  101. Sairanen E, Laaksonen AL. The toxicity of gold therapy in children suffering from rheumatoid arthritis. Ann Paediatr Fenn 1962; 8: 105

    PubMed  CAS  Google Scholar 

  102. Sairanen E, Laaksonen AL. The results of gold therapy in juvenile rheumatoid arthritis. Ann Paediatr Fenn 1963; 10: 274

    Google Scholar 

  103. Hicks RM, Hanson V, Kornreich HK. The use of gold in the treatment of juvenile rheumatoid arthritis [abstract]. Arthritis Rheum 1970; 13: 323

    Google Scholar 

  104. Debendetti C, Tretbar H, Corrigan JJJ. Gold therapy in juvenile rheumatoid arthritis. Ariz Med 1976; 33: 373–6

    PubMed  CAS  Google Scholar 

  105. Levinson JE, Balz GP, Bondi S. Gold therapy. Arthritis Rheum 1977; 20: 531–5

    PubMed  CAS  Google Scholar 

  106. Makela AL, Peltola O, Makela P. Gold serum levels in children with juvenile rheumatoid arthritis. Scand J Rheumatol 1978; 7: 161–5

    Article  PubMed  CAS  Google Scholar 

  107. Brewer EJJ, Giannini EH, Barkley E. Gold therapy in the management of juvenile rheumatoid arthritis. Arthritis Rheum 1980; 23: 404–11

    Article  PubMed  Google Scholar 

  108. Ansell BM, Hall MA, Ribero S. A comparative study of gold and penicillamine in seropositive juvenile chronic arthritis (juvenile rheumatoid arthritis) [abstract]. Ann Rheum Dis 1981; 40: 522

    Google Scholar 

  109. Ansell BM, Hall MA. Penicillamine in chronic arthritis of childhood. J Rheumatol Suppl 1981; 7: 112–5

    PubMed  CAS  Google Scholar 

  110. Kvien TK, Hoyeraal HM, Sandstad B. Gold sodium thiomalate and D-penicillamine: a controlled, comparative study in patients with pauciarticular and polyarticular juvenile rheumatoid arthritis. Scand J Rheumatol 1985; 14: 346–54

    Article  PubMed  CAS  Google Scholar 

  111. Research Subcommittee of the Empire Rheumatism Council. Gold therapy in rheumatoid arthritis: final report of a multi-centre controlled trial. Ann Rheum Dis 1961; 20: 315–33

    Article  Google Scholar 

  112. Kvien TK, Hoyeraal HM, Sandstad B. Slow acting antirheumatic drugs in patients with juvenile rheumatoid arthritis: evaluated in a randomized, parallel 50-week clinical trial. J Rheumatol 1985; 12: 533–9

    PubMed  CAS  Google Scholar 

  113. Adachi JD, Bensen WG, Kassam Y, et al. Gold-induced throm-bocytopenia: 12 cases and a review of the literature. Semin Arthritis Rheum 1987; 16: 287–93

    Article  PubMed  CAS  Google Scholar 

  114. Amos RS, Bax DE. Leucopenia in rheumatoid arthritis: relationship to gold or sulphasalazine therapy. Br J Rheumatol 1988; 27: 465–8

    Article  PubMed  CAS  Google Scholar 

  115. Giannini EH, Brewer EJJ, Kuzmina N, et al. Auranofin in the treatment of juvenile rheumatoid arthritis: results of the USA-USSR double-blind, placebo-controlled trial. The USA Pediatric Rheumatology Collaborative Study Group. The USSR Cooperative Children’s Study Group. Arthritis Rheum 1990; 33: 466–76

    CAS  Google Scholar 

  116. Ansell BM, Hall MA, Loftus JK, et al. A multicentre pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol 1991; 9: 201–3

    PubMed  CAS  Google Scholar 

  117. Ozdogan H, Turunc M, Deringol B, et al. Sulphasalazine in the treatment of juvenile rheumatoid arthritis: a preliminary open trial. J Rheumatol 1986; 13: 124–5

    PubMed  CAS  Google Scholar 

  118. van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998; 41: 808–16

    Article  PubMed  Google Scholar 

  119. Schairer H, Stoeber E. Long-term follow-up of 235 cases of juvenile rheumatoid arthritis treated with D-penicillamine. In: Munthe E, editor. Penicillamine research in rheumatoid disease. Oslo: Fabricius and Sonner, 1977: 279–81

    Google Scholar 

  120. Prieur AM, Piussan C, Manigne P, et al. Evaluation of D-penicillamine in juvenile chronic arthritis: a double-blind, multi-center study. Arthritis Rheum 1985; 28: 376–82

    Article  PubMed  CAS  Google Scholar 

  121. Enzenauer RJ, West SG, Rubin RL. D-penicillamine-induced lupus erythematosus. Arthritis Rheum 1990; 33: 1582–5

    Article  PubMed  CAS  Google Scholar 

  122. Wooley PH, Griffin J, Panayi GS, et al. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl JMed 1980; 303: 300–2

    Article  CAS  Google Scholar 

  123. Groothoff JW, van Leeuwen EF. High dose intravenous gamma-globulin in chronic systemic juvenile arthritis. Br Med J (Clin Res Ed) 1988; 296: 1362–3

    Article  CAS  Google Scholar 

  124. Stein LD, Roifman CM. Intravenous immunoglobulin therapy. Bull Rheum Dis 1995; 44: 3–5

    PubMed  CAS  Google Scholar 

  125. Prieur AM. Intravenous immunoglobulins in Still’s disease: still controversial, still unproven [editorial]. J Rheumatol 1996; 23: 797–800

    PubMed  CAS  Google Scholar 

  126. Silverman ED, Cawkwell GD, Lovell DJ, et al. Intravenous immunoglobulin in the treatment of systemic juvenile rheumatoid arthritis: a randomized, placebo-controlled trial. Pediatric Rheumatology Collaborative Study Group. J Rheumatol 1994; 21: 2353–8

    CAS  Google Scholar 

  127. Silverman ED, Laxer RM, Greenwald M, et al. Intravenous gamma globulin therapy in systemic juvenile rheumatoid arthritis. Arthritis Rheum 1990; 33: 1015–22

    Article  PubMed  CAS  Google Scholar 

  128. Uziel Y, Laxer RM, Schneider R, et al. Intravenous immunoglobulin therapy in systemic onset juvenile rheumatoid arthritis: a follow-up study. J Rheumatol 1996; 23: 910–8

    PubMed  CAS  Google Scholar 

  129. Prieur AM, Adleff A, Debre M, et al. High dose immunoglobulin therapy in severe juvenile chronic arthritis: long-term follow-up in 16 patients. Clin Exp Rheumatol 1990; 8: 603–8

    PubMed  CAS  Google Scholar 

  130. Giannini EH, Lovell DJ, Silverman ED, et al. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: a phase I/II study. Pediatrie Rheumatology Collaborative Study Group. J Rheumatol 1996; 23: 919–24

    CAS  Google Scholar 

  131. Myers BD, Ross J, Newton L, et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699–705

    Article  PubMed  CAS  Google Scholar 

  132. Palestine AG, Austin HA, Balow JE, et al. Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 1986; 314: 1293–8

    Article  PubMed  CAS  Google Scholar 

  133. van den Borne BE, Landewe RB, Houkes I, et al. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum 1998; 41: 1930–7

    Article  PubMed  Google Scholar 

  134. Bjerkhoel F, Forre O. Cyclosporin treatment of a patient with severe systemic juvenile rheumatoid arthritis. Scand J Rheumatol 1988; 17: 483–6

    Article  PubMed  CAS  Google Scholar 

  135. Ostensen M, Hoyeraal HM, Kass E. Tolerance of cyclosporine A in children with refractory juvenile rheumatoid arthritis. J Rheumatol 1988; 15: 1536–8

    PubMed  CAS  Google Scholar 

  136. Reiff A, Rawlings DJ, Shaham B, et al. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol 1997; 24: 2436–43

    PubMed  CAS  Google Scholar 

  137. Mouy R, Stephan JL, Pillet P, et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 1996; 129: 750–4

    Article  PubMed  CAS  Google Scholar 

  138. Laaksonen AL, Sunell JE, Westeren H, et al. Adrenocortical function in children with juvenile rheumatoid arthritis and other connective tissue disorders. Scand J Rheumatol 1974; 3: 137–42

    Article  PubMed  CAS  Google Scholar 

  139. Schaller JG. Corticosteroids in juvenile rheumatoid arthritis. Arthritis Rheum 1977; 20: 537–43

    Article  PubMed  CAS  Google Scholar 

  140. Stoeber E. Juvenile chronic polyarthritis and Still’s syndrome. Doc Geigy 1977; 1

  141. Prieur AM. The place of corticosteroid therapy in juvenile chronic arthritis in 1992. J Rheumatol Suppl 1993; 37: 32–4

    PubMed  CAS  Google Scholar 

  142. Southwood TR. Report from a symposium on corticosteroid therapy in juvenile chronic arthritis. Clin Exp Rheumatol 1993; 11: 91–4

    PubMed  CAS  Google Scholar 

  143. Axelrod L. Glucocorticoid therapy. Medicine (Baltimore) 1976; 55: 39–65

    Article  CAS  Google Scholar 

  144. Slocumb CH. Relative cortisone deficiency simulating exacerbation of arthritis. Bull Rheum Dis 1952; 3: 21

    PubMed  CAS  Google Scholar 

  145. Miller JJ. Prolonged use of large intravenous steroid pulses in the rheumatic diseases of children. Pediatrics 1980; 65: 989–94

    PubMed  Google Scholar 

  146. Oppermann J, Mobius D. Therapeutical and immunological effects of methylprednisolone pulse therapy in comparison with intravenous immunoglobulin: treatment in patients with juvenile chronic arthritis. Acta Univ Carol [Med] (Praha) 1994; 40: 117–21

    CAS  Google Scholar 

  147. Adebajo AO, Hall MA. The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis. Br J Rheumatol 1998; 37: 1240–2

    Article  PubMed  CAS  Google Scholar 

  148. Klein-Gitelman MS, Pachman LM. Intravenous corticosteroids: adverse reactions are more variable than expected in children. J Rheumatol 1998; 25: 1995–2002

    PubMed  CAS  Google Scholar 

  149. Kanski JJ. Anterior uveitis in juvenile rheumatoid arthritis. Arch Ophthalmol 1977; 95: 1794–7

    Article  PubMed  CAS  Google Scholar 

  150. Allen RC, Gross KR, Laxer RM, et al. Intraarticular triamcinolone hexacetonide in the management of chronic arthritis in children. Arthritis Rheum 1986; 29: 997–1001

    Article  PubMed  CAS  Google Scholar 

  151. Earley A, Cuttica RJ, McCullough C, et al. Triamcinolone into the knee joint in juvenile chronic arthritis. Clin Exp Rheumatol 1988; 6: 153–5

    PubMed  CAS  Google Scholar 

  152. Sparling M, Malleson P, Wood B, et al. Radiographic followup of joints injected with triamcinolone hexacetonide for the management of childhood arthritis. Arthritis Rheum 1990; 33: 821–6

    Article  PubMed  CAS  Google Scholar 

  153. Job-Deslandre C, Menkes CJ. Complications of intra-articular injections of triamcinolone hexacetonide in chronic arthritis in children. Clin Exp Rheumatol 1990; 8: 413–6

    PubMed  CAS  Google Scholar 

  154. Hertzberger-ten CR, Cats A. Toxicity of sulfasalazine in systemic juvenile chronic arthritis. Clin Exp Rheumatol 1991; 9: 85–8

    Google Scholar 

  155. Dent PB, Walker N. Intra-articular corticosteroids in the treatment of juvenile rheumatoid arthritis. Curr Opin Rheumatol 1998; 10: 475–80

    Article  PubMed  CAS  Google Scholar 

  156. Kvien TK, Hoyeraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double-blind comparative study. J Rheumatol 1986; 13: 118–23

    PubMed  CAS  Google Scholar 

  157. Savolainen HA, Kautiainen H, Isomaki H, et al. Azathioprine in patients with juvenile chronic arthritis: a longterm follow-up study. J Rheumatol 1997; 24: 2444–50

    PubMed  CAS  Google Scholar 

  158. Shaikov AV, Maximov AA, Speransky AI, et al. Repetitive use of pulse therapy with methylprednisolone and cyclophosphamide in addition to oral methotrexate in children with systemic juvenile rheumatoid arthritis: preliminary results of a long term study. J Rheumatol 1992; 19: 612–6

    PubMed  CAS  Google Scholar 

  159. Lehman TJ. Aggressive therapy for childhood rheumatic diseases: when are immunosuppressives appropriate? Arthritis Rheum 1993; 36: 71–4

    Article  PubMed  CAS  Google Scholar 

  160. Wallace CA, Sherry DD. Trial of intravenous pulse cyclophos-phamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40: 1852–5

    Article  PubMed  CAS  Google Scholar 

  161. Savolainen HA, Isomaki HA. Decrease in the number of deaths from secondary amyloidosis in patients with juvenile rheumatoid arthritis. J Rheumatol 1993; 20: 1201–3

    PubMed  CAS  Google Scholar 

  162. Ansell BM. Chlorambucil therapy in juvenile chronic arthritis (juvenile idiopathic arthritis). [editorial] J Rheumatol 1999; 26: 765–6

    PubMed  CAS  Google Scholar 

  163. Laxer RM. Long-term toxicity of immune suppression in juvenile rheumatic diseases. Br J Rheumatol 1999; 38: 743–6

    Article  CAS  Google Scholar 

  164. Prieur AM, Balafrej M, Griscelli C, et al. Results and long-term risks of immuno-suppressive treatment in chronic juvenile arthritis: apropos of 40 cases [in French]. Rev Rhum Mal Osteoartic 1979; 46: 85–90

    PubMed  CAS  Google Scholar 

  165. Buriot D, Prieur AM, Lebranchu Y, et al. Acute leukemia in 3 children with chronic juvenile arthritis treated with chlorambucil [in French]. Arch Fr Pediatr 1979; 36: 592–8

    PubMed  CAS  Google Scholar 

  166. Ansell BM, Eghtedari A, Bywaters EG. Chlorambucil in the management of juvenile chronic polyarthritis complicated by amyloidosis. Ann Rheum Dis 1971; 30: 331

    Article  PubMed  CAS  Google Scholar 

  167. Deschenes G, Prieur AM, Hayem F, et al. Renal amyloidosis in juvenile chronic arthritis: evolution after chlorambucil treatment. Pediatr Nephrol 1990; 4: 463–9

    Article  PubMed  CAS  Google Scholar 

  168. Rostropowicz-Denisiewicz K. Some remarks on management of juvenile chronic arthritis complicated by amyloidosis. Acta Univ Carol [Med] (Praha) 1994; 40: 91–4

    CAS  Google Scholar 

  169. Savolainen HA. Chlorambucil in severe juvenile chronic arthritis: long term follow-up with special reference to amyloidosis. J Rheumatol 1999; 26: 898–903

    PubMed  CAS  Google Scholar 

  170. Weaver A, Caldwell J, Olsen N. Treatment of active rheumatoid arthritis with leflunomide compared to placebo or methotrexate. Arthritis Rheum 1998; 41: S131

    Google Scholar 

  171. Rozman B. Clinical experience with leflunomide in rheumatoid arthritis. Leflunomide Investigators’ Group. J Rheumatol Suppl 1998; 53: 27–32

    CAS  Google Scholar 

  172. Weinblatt ME, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1322–8

    Article  PubMed  CAS  Google Scholar 

  173. Lovell DJ, Giannini EH, Whitmore JB, et al. Safety and efficacy of tumor necrosis factor receptor P75 FC fusion protein (TNFR: FC; Enbrel TM) in polyarticular course juvenile rheumatoid arthritis [abstract]. Arthritis Rheum 1998; 41 (Suppl.): S130

    Article  Google Scholar 

  174. Keystone EC. The role of tumor necrosis factor antagonism in clinical practice. J Rheumatol 1999; 26 Suppl. 57: 22–8

    Google Scholar 

  175. Moreland LW. Inhibitors of tumor necrosis factor for rheumatoid arthritis. J Rheumatol 1999; 26 Suppl. 57: 7–15

    Google Scholar 

  176. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130: 478–86

    PubMed  CAS  Google Scholar 

  177. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9

    Article  PubMed  CAS  Google Scholar 

  178. Jones RE, Moreland LW. Tumor necrosis factor inhibitors for rheumatoid arthritis. Bull Rheum Dis 1999; 48: 1–4

    PubMed  Google Scholar 

  179. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105–10

    Article  PubMed  CAS  Google Scholar 

  180. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125–7

    Article  PubMed  CAS  Google Scholar 

  181. Maini RN, Elliott M, Brennan FM, et al. Targeting TNF alpha for the therapy of rheumatoid arthritis. Clin Exp Rheumatol 1994; 12 Suppl. 11: S63–6

    PubMed  Google Scholar 

  182. Elliott MJ, Woo P, Charles P, et al. Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). Br J Rheumatol 1997; 36: 589–93

    Article  PubMed  CAS  Google Scholar 

  183. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552–63

    Article  PubMed  CAS  Google Scholar 

  184. Choy EH, Kingsley GH, Panayi GS. Monoclonal antibody therapy in rheumatoid arthritis. Br J Rheumatol 1998; 37: 484–490

    Article  PubMed  CAS  Google Scholar 

  185. Rau R, Sander O, den Breeder A, et al. Long-term efficacy and tolerability of multiple I.V. doses of a fully human anti-TNF-antibody D2E7 in patients with rheumatoid arthritis. Arthritis Rheum 1998; 41: S55

    Google Scholar 

  186. Wulffraat N, van Royen A, Bierings M, et al. Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis. Lancet 1999; 353: 550–3

    Article  PubMed  CAS  Google Scholar 

  187. Quartier P, Prieur AM, Fischer A. Haemopoietic stem-cell transplantation for juvenile chronic arthritis [letter]. Lancet 1999; 353: 1885–6

    Article  PubMed  CAS  Google Scholar 

  188. Kuis W, Wulffraat NM, Petty RE. Autologous stem cell transplantation: an alternative for refractory juvenile chronic arthritis. Br J Rheumatol 1999; 38: 737–8

    Article  CAS  Google Scholar 

  189. Wulffraat NM, Kuis W Autologous stem cell transplantation: a possible treatment for refractory juvenile chronic arthritis? Br J Rheumatol 1999; 38: 764–6

    Article  CAS  Google Scholar 

  190. Wulffraat NM, Kuis W, Petty R. Addendum: proposed guidelines for autologous stem cell transplantation in juvenile chronic arthritis. Br J Rheumatol 1999; 38: 777–8

    Article  CAS  Google Scholar 

  191. Johansson U, Portinsson S, Akesson A, et al. Nutritional status in girls with juvenile chronic arthritis. Hum Nutr Clin Nutr 1986; 40: 57–67

    PubMed  CAS  Google Scholar 

  192. Mortensen AL, Allen JR, Allen RC. Nutritional assessment of children with juvenile chronic arthritis. J Paediatr Child Health 1990; 26: 335–8

    Article  PubMed  CAS  Google Scholar 

  193. Henderson CJ, Lovell DJ, Specker BL, et al. Physical activity in children with juvenile rheumatoid arthritis: quantification and evaluation. Arthritis Care Res 1995; 8: 114–9

    Article  PubMed  CAS  Google Scholar 

  194. Henderson CJ, Lovell DJ. Nutritional aspects of juvenile rheumatoid arthritis. Rheum Dis Clin North Am 1991; 17: 403–13

    PubMed  CAS  Google Scholar 

  195. Knops N, Wulffraat N, Lodder S, et al. Resting energy expenditure and nutritional status in children with juvenile rheumatoid arthritis. J Rheumatol 1999; 26: 2039–43

    PubMed  CAS  Google Scholar 

  196. Rapoff MA, Purviance MR, Lindsley CB. Educational and behavioral strategies for improving medication compliance in juvenile rheumatoid arthritis. Arch Phys Med Rehabil 1988; 69: 439–41

    PubMed  CAS  Google Scholar 

  197. Donovan WH. Physical measures in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 1977; 20: 553–7

    PubMed  CAS  Google Scholar 

  198. Scull SA, Dow MB, Athreya BH. Physical and occupational therapy for children with rheumatic diseases. Pediatr Clin North Am 1986; 33: 1053–77

    PubMed  CAS  Google Scholar 

  199. Emery HM, Kucinski J. Management of juvenile rheumatoid arthritis: a handbook for occupational and physical therapists. Chicago (IL): LaRabida Children’s Hospital and Research Center, 1987

    Google Scholar 

  200. Fan JS, Wessel J, Ellsworth J. The relationship between strength and function in females with juvenile rheumatoid arthritis. J Rheumatol 1998; 25: 1399–405

    PubMed  CAS  Google Scholar 

  201. Hackett J, Johnson B, Parkin A, et al. Physiotherapy and occupational therapy for juvenile chronic arthritis: custom and practice in five centres in the UK, USA and Canada. Br J Rheumatol 1996; 35: 695–9

    Article  CAS  Google Scholar 

  202. Petty RE. Prognosis in children with rheumatic diseases: justification for consideration of new therapies. Br J Rheumatol 1999; 38: 739–42

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Child Health, University of Missouri, Columbia, Missouri, 65212, USA

    James T. Cassidy

Authors
  1. James T. Cassidy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James T. Cassidy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cassidy, J.T. Medical Management of Children with Juvenile Rheumatoid Arthritis. Drugs 58, 831–850 (1999). https://doi.org/10.2165/00003495-199958050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199958050-00006

Keywords

Search

Navigation